{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04905914",
            "orgStudyIdInfo": {
                "id": "AR-276-01"
            },
            "organization": {
                "fullName": "Aprea Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study Of ATRN-119 In Patients With Advanced Solid Tumors",
            "officialTitle": "A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors",
            "acronym": "ABOYA-119",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-atrn-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-17",
            "studyFirstSubmitQcDate": "2021-05-24",
            "studyFirstPostDateStruct": {
                "date": "2021-05-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Aprea Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "3+3 Dose escalation design",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "50mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                },
                {
                    "label": "100mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                },
                {
                    "label": "200mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                },
                {
                    "label": "350mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                },
                {
                    "label": "550mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                },
                {
                    "label": "800mg ATRN-119",
                    "type": "EXPERIMENTAL",
                    "description": "Once daily oral administration.",
                    "interventionNames": [
                        "Drug: ATRN-119"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ATRN-119",
                    "description": "ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.",
                    "armGroupLabels": [
                        "100mg ATRN-119",
                        "200mg ATRN-119",
                        "350mg ATRN-119",
                        "50mg ATRN-119",
                        "550mg ATRN-119",
                        "800mg ATRN-119"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics",
                    "description": "Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed",
                    "timeFrame": "Day 1 to Day 56"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.\n* Measurable disease defined by RECIST 1.1.\n* Life expectancy \u2265 3 months.\n* Subject must be capable of oral administration of study medication.\n\nExclusion Criteria:\n\n* Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.\n* Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.\n* Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.\n* Known human immunodeficiency virus infection (HIV).\n* Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.\n* Current or past diagnosis of leukemia within the past 5 years.\n* Prior radiotherapy at the target lesion unless there is evidence of disease progression.\n* Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging \\[MRI\\] brain).\n* History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.\n* Patient has uncontrolled hypertension at time of enrollment.\n* Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block \\[RBBB\\] with either left anterior hemiblock or left posterior hemiblock).\n* Any clinically significant ST segment and/or T-wave abnormalities.\n* Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Crystal Miller, RN BSN",
                    "role": "CONTACT",
                    "phone": "1 617 463 9385",
                    "email": "crystal.miller@aprea.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Crystal Miller, RN BSN",
                    "affiliation": "Aprea Therapeutics Inc",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yale Cancer Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520-8028",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ingrid Palma",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "email": "Ingrid.palma@yale.edu"
                        },
                        {
                            "name": "Patricia LoRusso, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "University Hospitals, Cleveland Medical Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amit Mahipal, MD",
                            "role": "CONTACT",
                            "phone": "800-641-2422"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Fiona Simpkins, MD",
                            "role": "CONTACT",
                            "phone": "215-220-9519",
                            "email": "PerelmanGyn/OncResearchCoordinatorPool@uphs.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}